Predictors of responsiveness to opioid analgesic medications are not well understood. This study tested whether individual differences in endogenous opioid (EO) function are associated with analgesic responsiveness to morphine. In randomized, counterbalanced order over 3 sessions, 45 chronic low back pain participants and 31 healthy controls received an opioid antagonist (8 mg naloxone), morphine (0.08 mg/kg), or placebo. Participants then engaged in 2 laboratory-evoked pain tasks (ischemic and thermal). Outcomes included pain threshold, pain tolerance, and pain ratings. Indexes of EO function and morphine analgesic responsiveness were derived for each measure as the difference in pain responses between the placebo condition and naloxone or morphine condition, respectively. For all 7 pain measures across the 2 laboratory pain tasks, greater EO function was associated with significantly lower morphine analgesic responsiveness (P < 0.001-P = 0.02). Morphine reduced pain responses of low EO individuals to levels similar to those of high EO individuals receiving placebo. Higher placebo condition-evoked pain sensitivity was associated with significantly greater morphine analgesic responsiveness for 5 of 7 pain measures (P < 0.001-P = 0.02). These latter associations were significantly mediated by EO function for 4 of these 5 pain outcomes (all P values < 0.05). In the laboratory-evoked pain context, opioid analgesic medications may supplement inadequate EO analgesia, with little incremental benefit in those with preexisting high EO function. Implications for personalized medicine are discussed. Ó
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Introduction
The concept of personalized medicine, optimizing medications for individual patients based on genetic, biomarker, and other patient-related factors, has received increasing attention [25, 32] . Its potential application to the field of pain medicine is tantalizing, although supporting data are as yet inadequate [6] . Factors that determine, and could be clinical predictors of, responses to commonly used opioid analgesic medications are not fully understood. One surprising gap in this literature is the absence of human studies addressing the impact of individual differences in endogenous opioid (EO) system function on responses to opioid analgesic medications. Such interactions might be expected given that both EOs and opioid medications act on the same opioid receptors [41] . Animal studies suggest that EO function does influence opioid analgesic responses, although direction of these effects appears inconsistent. Although several animal studies indicate possible cross-tolerance between EOs and opioid analgesic medications [22, 36, 48] , others suggest synergistic effects, with direct application of EOs (e.g., b-endorphin) or manipulations that trigger release of EOs (e.g., forced swim, tail suspension, exercise) enhancing responsiveness to opioid analgesics [2,5,12,13,17,31,46,47,49,50]. Human positron emission tomography imaging findings are indirectly supportive as well, indicating that a placebo manipulation with EO enhancing effects [20] increases opioid analgesic responses [4] . Improved knowledge regarding the impact of EO system function on responses to opioid analgesic medications in humans might facilitate progress toward the goal of personalized pain medicine.
One individual difference factor previously reported to predict opioid analgesic responses in humans is sensitivity to laboratory
